The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, T Shah, R Sofat, Y Guo, C Chung, Anne Peasey, Nicholas J Timpson, Juan Pablo Casas

Research output: Contribution to journalArticle (Academic Journal)peer-review

511 Citations (Scopus)
641 Downloads (Pure)

Abstract

A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.
Original languageEnglish
Pages (from-to)1214-1224
Number of pages11
JournalLancet
Volume379
Issue number9822
Early online date12 Mar 2013
DOIs
Publication statusPublished - 31 Mar 2013

Fingerprint Dive into the research topics of 'The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis'. Together they form a unique fingerprint.

Cite this